After various positions in the United Kingdom, Dalgleish joined the flying doctor service in Mount Isa, Queensland, then progressed through positions at various hospitals in Brisbane, Australia before moving to the Ludwig Institute for Cancer Research in Sydney.
In 1997, he founded Onyvax Ltd., a privately funded biotechnology company developing cancer vaccines, where he holds a position as Research Director.
WIPO ASSIGNS PATENT TO BIONOR IMMUNO FOR "HIV RELATED PEPTIDES COMBINATION OR FUSION FOR USE IN HIV VACCINE COMPOSITION OR AS DIAGNOSTIC MEANS" (NORWEGIAN, SWEDISH, BRITISH INVENTORS)
Aug 24, 2011; GENEVA, Aug. 24 -- Publication No. WO/2011/000962 was published on Jan. 06. Title of the invention: "HIV RELATED PEPTIDES...
Immunosyn Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019.
Jan 28, 2008; Immunosyn Corporation (BULLETIN BOARD: IMYN) announced that the first phase of a formal "Proof of Concept Trial" for the...